Potential biomarkers to assess may include circulating soluble tumour necrosis factor receptor‐2 (Epstein et al., 2018), C‐reactive protein, insulin‐like growth factor‐1 and lactate dehydrogenase (for cancer in general) (Desai & Guddati, 2023; Feng et al., 2018; Zhang et al., 2024), testosterone and prolactin (in women, for breast cancer) (Aranha et al., 2022; Zhang et al., 2024), and prostate‐specific antigen and novel associated markers (Garrido et al., 2022) as well as coagulation markers (Lei et al., 2023) (in men, for prostate cancer). Here, PRL is linked to prostate carcinoma.